Figure 1. Ribociclib is a rational target in ovarian cancer.

(A) Analysis of 316 tumors from the TCGA database showing mutations and mRNA dysregulation of genes known to regulate the G1-S phase transition. (B) Cell numbers as a proportion of untreated control cell numbers in the indicated cell lines after 72 hours of treatment with the indicated doses of Ribociclib. (C) Fold-change in cell number over time in Hey1 cells (Rb^WT) treated with the indicated doses of Ribociclib. (D) Fold-change in cell number over time in COV362 cells (Rb^null) treated with the indicated doses of Ribociclib. (E) Analysis of cellular viability in Hey1 cells treated with the indicated doses of Ribociclib. All samples were analyzed at least in triplicate with each experiment performed three times. ^*p < 0.05, ^**p < 0.01, ^***p < 0.001, ^****p<0.0001 by two-sample, two-tailed t-tests comparing the indicated values in C and D and one-way ANOVA comparing groups in B.